

RESEARCH ARTICLE

Open Access



# Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer's disease

Olav M. Andersen<sup>1\*†</sup>, Matthijs W. J. de Waal<sup>2,3†</sup> , Giulia Monti<sup>1</sup>, Niccolo Tesi<sup>2,3,4,5</sup>, Anne Mette G. Jensen<sup>1</sup>, Christa de Geus<sup>6</sup>, Rosalina van Spaendonk<sup>7</sup>, Maartje Vogel<sup>7</sup>, Shahzad Ahmad<sup>8,9</sup>, Najaf Amin<sup>8,10</sup>, Philippe Amouyel<sup>11</sup>, Gary W. Beecham<sup>12</sup>, Céline Bellenguez<sup>11</sup>, Claudine Berr<sup>13</sup>, Joshua C. Bis<sup>14</sup>, Anne Boland<sup>15</sup>, Paola Bossù<sup>16</sup>, Femke Bouwman<sup>3,4</sup>, Jose Bras<sup>17,18</sup>, Camille Charbonnier<sup>19</sup>, Jordi Clarimon<sup>20,21</sup>, Carlos Cruchaga<sup>22,23,24</sup>, Antonio Daniele<sup>25</sup>, Jean-François Dartigues<sup>26</sup>, Stéphanie Debette<sup>26,27</sup>, Jean-François Deleuze<sup>15</sup>, Nicola Denning<sup>28</sup>, Anita L. DeStefano<sup>29,30,31</sup>, Oriol Dols-Icardo<sup>20,21</sup>, Cornelia M. van Duijn<sup>8,10</sup>, Lindsay A. Farrer<sup>29,30,31,32,33</sup>, Maria Victoria Fernández<sup>22,23,24</sup>, Wiesje M. van der Flier<sup>3,4</sup>, Nick C. Fox<sup>34,35</sup>, Daniela Galimberti<sup>36,37</sup>, Emmanuelle Genin<sup>38</sup>, Johan J. P. Gille<sup>7</sup>, Benjamin Grenier-Boley<sup>11</sup>, Detelina Grozeva<sup>39</sup>, Yann Le Guen<sup>40</sup>, Rita Guerreiro<sup>17,18</sup>, Jonathan L. Haines<sup>41</sup>, Clive Holmes<sup>42</sup>, Holger Hummerich<sup>43</sup>, M. Arfan Ikram<sup>8</sup>, M. Kamran Ikram<sup>8</sup>, Amit Kawalia<sup>44</sup>, Robert Kraaij<sup>45</sup>, Jean-Charles Lambert<sup>11</sup>, Marc Lathrop<sup>46</sup>, Afina W. Lemstra<sup>3,4</sup>, Alberto Lleó<sup>20,21</sup>, Richard M. Myers<sup>47</sup>, Marcel M. A. M. Mannens<sup>48</sup>, Rachel Marshall<sup>39</sup>, Eden R. Martin<sup>12,49</sup>, Carlo Masullo<sup>50</sup>, Richard Mayeux<sup>51,52</sup>, Simon Mead<sup>43</sup>, Patrizia Mecocci<sup>53,54</sup>, Alun Meggy<sup>28</sup>, Merel O. Mol<sup>55</sup>, Benedetta Nacmias<sup>56,57</sup>, Adam C. Naj<sup>58,59</sup>, Valerio Napolioni<sup>40,60</sup>, J. Nicholas Cochran<sup>47</sup>, Gaël Nicolas<sup>19</sup>, Florence Pasquier<sup>61</sup>, Pau Pastor<sup>62,63</sup>, Margaret A. Pericak-Vance<sup>12,49</sup>, Yolande A. L. Pijnenburg<sup>3,4</sup>, Fabrizio Piras<sup>64</sup>, Olivier Quenez<sup>19</sup>, Alfredo Ramirez<sup>44,65,66,67,68</sup>, Rachel Raybould<sup>28</sup>, Richard Redon<sup>69</sup>, Marcel J. T. Reinders<sup>5</sup>, Anne-Claire Richard<sup>19</sup>, Steffi G. Riedel-Heller<sup>70</sup>, Fernando Rivadeneira<sup>45</sup>, Jeroen G. J. van Rooij<sup>45,55</sup>, Stéphane Rousseau<sup>19</sup>, Natalie S. Ryan<sup>34,35</sup>, Pascual Sanchez-Juan<sup>21,71</sup>, Gerard D. Schellenberg<sup>58</sup>, Philip Scheltens<sup>3,4</sup>, Jonathan M. Schott<sup>34,35</sup>, Sudha Seshadri<sup>30,31,66</sup>, Daoud Sie<sup>7</sup>, Rebecca Sims<sup>39</sup>, Erik A. Sijtemans<sup>2,48</sup>, Sandro Sorbi<sup>56,57</sup>, John C. van Swieten<sup>55</sup>, Betty Tijms<sup>3,4</sup>, André G. Uitterlinden<sup>45</sup>, Pieter Jelle Visser<sup>3,4</sup>, Michael Wagner<sup>67,68</sup>, David Wallon<sup>19</sup>, Li-San Wang<sup>58</sup>, Julie Williams<sup>39,72</sup>, Jennifer S. Yokoyama<sup>73</sup>, Aline Zarea<sup>19</sup>, Sven J. van der Lee<sup>2,3,4</sup>, Johan G. Olsen<sup>74</sup>, Marc Hulsman<sup>2,3,4,5</sup> and Henne Holstege<sup>2,3,4,5\*†</sup>

<sup>†</sup>Olav M. Andersen, Matthijs W. J. de Waal and Henne Holstege contributed equally to this work.

\*Correspondence:

Olav M. Andersen  
o.andersen@biomed.au.dk  
Henne Holstege  
h.holstege@amsterdamumc.nl

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Abstract

**Background** Protein truncating variants (PTVs) in *SORL1* are observed almost exclusively in Alzheimer's Disease (AD) cases, but the effect of rare *SORL1* missense variants is unclear.

**Methods** To identify high-priority missense variants (HPVs), we applied 'domain mapping of disease mutations' for the 637 unique coding *SORL1* variants detected in 18,959 AD-cases and 21,893 non-demented controls.

**Results** In this sample, PTVs and HPVs associated with respectively a 35- and 10-fold increased risk of early onset AD and 17- and 6-fold increased risk of overall AD. The median age at onset (AAO) of PTV- and HPV-carriers was 62 and 64 years, and *APOE*-genotype contributed to AAO-variability. The median AAO of PTV- and HPV-carriers is ~8–10 years earlier than wild-type *SORL1* carriers, matched for *APOE*-genotype. Specific HPVs are highly penetrant and lead to earlier AAOs than PTVs, suggesting possible dominant negative effects.

**Conclusion** Our results justify a debate on whether HPV carriers should be considered for clinical counseling.

**Keywords** *SORL1*, *SORLA*, Alzheimer's disease, Genetics, Penetrance, Age at onset, Rare variants, Disease risk, Alzforum mutation database, Domain-mapping disease-mutations

## Background


The *SORL1* protein, or *SORLA*, encoded by the *SORL1* gene, is the cargo-binding entity of the *SORL1*-retromer complex which regulates cargo-transport from the endosome back to the trans-Golgi network ('retrograde' pathway) and the transport of endocytosed receptors back to the cell surface ('recycling' pathway). Among *SORL1*'s numerous cargo is Amyloid- $\beta$  and the amyloid precursor protein (APP): APP-binding by retromer-*SORL1* accelerates APP-trafficking out of the early endosome, thereby warding off APP-cleavage and the subsequent formation and secretion of Amyloid- $\beta$  [1], which links impaired *SORL1* with hallmark processes of Alzheimer's disease (AD). Genetic variants in *SORL1* have been linked to AD risk since 2007 [2]. Genome wide association studies (GWAS) reported that common single nucleotide polymorphisms (SNPs) in or near *SORL1* associated with AD, though with limited effects [3–6]. Furthermore, large case-control sequencing studies reported that rare coding variants in *SORL1* had a considerable effect on AD [7–11].

*SORL1* is a multidomain, 2,214 amino-acid protein, encoded by 48 exons, such that by virtue of its size, *SORL1* genetic sequence is vulnerable for acquiring mutations. More than 3,000 coding variants are listed in GnomAD [12], with effects ranging from negligible to deleterious on protein function. Potentially damaging *SORL1* variants affect as many as 2.75% of all genetically unrelated early onset AD cases (EOAD, with Age at Onset (AAO) < 65 years) and 1.5% of genetically unrelated late onset AD cases (LOAD, with AAO > 65 years) [13]. Of these, protein truncating variants (PTV) occur almost exclusively in AD cases [10, 13], suggesting that *SORL1*'s haploinsufficiency is highly penetrant and may be causative of AD [7, 10, 13, 14]. Indeed, a recent report described a Peruvian pedigree affected with a p.Trp1673Ter PTV with an inheritance pattern of AD

suggestive of autosomal dominant AD (ADAD) [15]. However, most *SORL1* variants observed in AD cases are rare missense *SORL1* variants, mostly unique to one person and their family-members, some may increase risk or cause disease, while many are benign [16–18].

In our clinics, we have identified several large families affected with (early onset) AD with an inheritance pattern suggestive of ADAD, in which the proband carries a *SORL1* variant. However, since DNA of affected and unaffected relatives is commonly unavailable for segregation analyses, it remains unclear whether the *SORL1* variant is the cause of the ADAD in these families [18]. Over the past years, several (assembled) pedigrees were reported that suggest high penetrance of specific *SORL1* variants [8, 14, 17–21]. However, in contrast to certain variants in the classic *PSEN1/PSEN2/APP* ADAD genes [22], no fully penetrant *SORL1* variants have been identified. While incomplete penetrance has been described in ADAD genes as well [23, 24], this lack of proper AD risk estimates associated with the diverse *SORL1* variants causes uncertainty of their clinical relevance. Consequently, even protein truncating variants in *SORL1* are classified as 'VUS': variant of unknown significance (ClinVar [25]) and such variants are not routinely communicated to patients, despite accumulating evidence that specific *SORL1* variants are highly penetrant [14]. For clinical geneticists to consider including *SORL1* variants in AD diagnostics a better understanding of *SORL1* variant pathogenicity and their effects on AAO is imperative.

Here, we took advantage of the increasing knowledge of *SORL1* function and structured domains (Fig. 1) and we learned from the effect of specific missense variants on the function of proteins that share domains with *SORL1*, such as those in the low-density-lipoprotein receptor (LDLR)-family and Fibronectin-like proteins, which are associated with familial diseases like Familial Hypercholesterolemia (FH) and holoprosencephaly (Fig. 2). This



(See figure on previous page.)

**Fig. 1** Schematic of the SORL1 domains and their function, highlighting the variants with the strongest effects on AD risk, that may exist in several domain-repeats. SORL1 is a large, 2,214 amino acid multi-domain protein, which includes multiple repeated domain elements, each of which includes many strictly or moderately conserved residues important for protein domain folding and/or the binding of ligands. When the SORL1 protein is transcribed at the ribosome, the protein signal peptide (res 1–28) is cleaved off upon translocation to the endoplasmic reticulum (ER). During its transport through the trans-Golgi-Network, the SORL1 protein undergoes several post-translational modifications, including *N*- and *O*-glycosylation at multiple sites [26, 27]. During this maturation process, the pro-domain (res 29–81) is speculated to prevent binding of certain ligands to the VPS10p-domain in the endoplasmic reticulum (ER), where receptor and ligand are co-expressed. The pro-domain is cleaved off by Furin once SORL1 leaves the trans-Golgi-Network, where it can engage in ligand binding and trafficking. The VPS10p-domain (res 82–617), a ten-bladed  $\beta$ -propeller domain, is a flat disc that is stabilized at its bottom face by the 10CC-domain (res 618–753). At its top face, the VPS10p-domain binds ligand, it further has a large hydrophobic tunnel at its center, allowing interaction with small lipophilic ligands such as the Amyloid- $\beta$  peptide. The domain contains two protrusions (loop structures, loop L1 and loop L2): the VPS10p-domain can bind ligand at neutral pH and while L1 blocks part of the tunnel, the L2 protrusion pushes the ligand against the tunnel wall. After trafficking to a more acidic part of the cell (i.e. The lysosome), L1 and L2 change conformation and release the ligands from the VPS10p pore. C-terminal to the 10CC-domain is a ligand-binding YWTD  $\beta$ -propeller (res 754–1013), which is stabilized at its bottom face by an EGF-domain (res 1014–1074, fully encoded by exon 22), such that ligand-interactions with both the VPS10p and YWTD  $\beta$ -propellers occur at their top faces. The combined action of VPS10p  $\beta$ -propeller and the YWTD  $\beta$ -propeller might enable interactions with large ligands including co-receptors in multimeric complexes, or large soluble ligands requiring two adjacent  $\beta$ -propellers for efficient binding, akin to what was recently identified for LRP4/Agrin/MusK signalling complex [28]. C-terminal to the EGF-domain comes the CR-cluster (res 1075–1550) which is the interacting site of at least half of the SORL1-ligands, including APP. This cluster is like a flexible necklace composed of 11 unique ~40 amino-acid CR-domains, each encoded by a single exon (exons 23–33), that each form the ‘pearls’ on the string. These can wrap around larger ligands and engage in minimal motif interactions with multiple sites of a ligand, leading to high-affinity ligand binding. Each CR-domain includes 16 strictly conserved amino acids, including six disulfide bridge-forming cysteines, such that all CR-domains have a similar compact folding. Each CR-domain further contains four conserved residues that form an octahedral ‘calcium-cage’ which stabilizes the domain, and in combination with two backbone carbonyls, coordinates a calcium ion, which is critical for calcium-dependent domain folding. The side chains of these two residues engage in minimal-motif ligand binding, which explains why ligand binding to CR-domains relies on  $\text{Ca}^{2+}$ . Substituting these may impair the binding of specific ligands, but do not affect overall folding and stability of CR-domains [29]. Preliminary evidence suggests that perturbation of the calcium-cage on the other hand, may lead to a misfolded SORL1 protein that is retained in the ER [30]. C-terminal of the CR-cluster is the 3FN-cassette (res 1551–2121), containing 6 ellipsoid 3FN-domains, each containing several conserved and partly conserved residues, and involved in SORL1 dimerization [31]. Therefore, genetic variants affecting one of the conserved residues in 3FN-domain is likely to disturb SORL1 dimerization [19]. Lastly, SORL1 has a transmembrane and cytoplasmic tail domain (res 2122–2214) which can interact with the VPS26 subunit of the retromer complex [32]. Recent evidence suggests that SORL1 matures (by *N*- and *O*-glycosylation) at the ER/Golgi in a monomer form, then travels to the endosome where it dimerizes at its 3FN-domain and its VPS10-domain [19]. The dimerized SORL1 uses its cytoplasmic tail domain to interact with the VPS26 subunit of the retromer complex, allowing SORL1 to engage in retromer-dependent cargo trafficking through the endolysosomal system. See the ‘Compendium’ and Fig S7–S14 in the Supplementary Data for a detailed description and an overview of variant prioritization per domain

observation allows for a domain-mapping of disease-mutations approach (DMDM) [33], tailored to prioritize functionally relevant *SORL1* variants according to pathogenicity observed for homologous amino acid positions. We applied this prioritization strategy to *SORL1* variants identified in sequencing data of 18,959 AD cases and 21,893 non-demented controls [13] and identified high-priority (HPV), moderate-priority (MPV), low-priority (LPV) and no-priority (NPV) missense variants. We investigated the AD risk and AAO of AD associated with variants from these groups, and further categorized high-priority missense variants into specific subcategories. With this work, we aim to provide insight into *SORL1* variant pathogenicity, and effects on AAO. With this, we aim to ultimately contribute to the discussion whether identifying and disclosing *SORL1* variant in AD patients is beneficial [34, 35].

## Methods


### Samples

We extracted *SORL1* genetic variants from the assembled whole exome sequencing (WES) and whole genome sequencing (WGS) data as previously described [13], which includes data contributed by the European ADES cohort and the ADSP, StEP-AD, Knight-ADRC and UCSF/NYGC/UAB cohorts, Procedures for AD diagnosis

were described previously [13], and occurred according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association criteria [36] or the National Institute on Aging-Alzheimer’s Association criteria [37]. Carriers of a pathogenic variant(s) in *PSEN1*, *PSEN2*, or *APP* or in any other gene associated with Mendelian dementia were excluded. Relatives up to 3<sup>rd</sup> degree of relatedness were excluded to avoid any family-based effects [38].

Variant carriers were identified by determining posterior genotype dosages, using genotype probabilities and the frequency of the variant in the dataset as a prior, allowing us to take genotyping uncertainty into account (previously described in Methods and Supplementary Note of Holstege and Hulsman et al., 2022 [13]). For analysis, we considered variants that had at least 1 carrier, that is, at least one sample with a posterior dosage > 0.5. Application of our comprehensive quality control procedures allowed the retention of more AD cases and controls for a *SORL1*-specific analysis, compared to our previously published genome-wide analysis [13]. We further increased analysis power by including *SORL1* variants identified in individuals with non-European ancestry, the rationale for this is that rare *SORL1* variants have been reported to associated with AD risk






**Fig. 2** Homologous proteins and diseases. Schematic representation of the structural elements of SORLA and members of the mammalian LDLR- and VPS10p receptor families. Clustered copies of 3Fn-domains close to the membrane is present in a large number of unrelated proteins with diverse function (only a small subset included), thus not enabling assignment to any class of unique proteins like the other two receptor families. Some of the diseases the homologous proteins can cause when hit by pathogenic variants are listed below individual proteins

across all populations studied thus far [39]. Together, after quality control (QC), the current sample included *SORL1* sequences from 40,852 individuals: 18,959 AD cases and 21,893 non-demented controls. To correct for population-specific effects, we performed a principal component analysis (PCA) including the first 6 principal

components (PCs) as covariates in our analysis. PCs were available for 95.6% of cases (18,126/18,959) and 93.8% of controls (20,546/21,893), which indicated that the sample comprised 12.9% African, 0.1% East Asian, 0.6% South Asian, 5.8% Admixed Americans and 80.6% European: for a PCA representing the sample by population



**Fig. 3** Flowchart of selection procedures for *SORL1* variant subtypes. \*non-coding variants were identified in the padding of exome sequencing or in exome excerpts from whole genome sequences. †variants were merged into one when they were juxtaposed and in cis. ‡the 27 individuals who carried more than one rare *SORL1* variant were grouped according to the variant with the highest priority. Among these was one case (AAO 46, *APOE*- $\epsilon$ 3/ $\epsilon$ 4) who carried a p.C1453F ONC variant in combination with a PTV, and one case (AAO 55, *APOE*- $\epsilon$ 3/ $\epsilon$ 4) carried a 11:121459965:T>TG splice variant in combination with a PTV; both were grouped with PTV carriers

background see Figure S1. *APOE* genotyping was available for 99.4% of cases (18,837/18,959) and 70.7% of controls (15,483/21,893). Missingness in *APOE* genotyping was due to GC-richness of the region encompassing the rs7412, that defines the *APOE* genotype which complicates variant-calling in exome sequencing. In AD cases, we supplemented missing *APOE* information by available genotyping, which was not available for controls.

#### Variant quality control

The raw sequence data was processed with a uniform pipeline as described previously [13]. In brief, the data was processed relative to the GRCh37 reference genome, after which extensive quality control was applied which led to the exclusion of likely false positive variant-calls from analysis. Other variants were excluded due to differential missingness, positions for which coverage across cases and controls differed >5%. These included

all variants in exon 1 (res 1–95), which codes for the signal peptide (res 1–28), the pro-domain (29–81), and the first 10 residues of the VPS10p-domain. See Table S3 for excluded variants.

#### Variant annotation

We annotated *SORL1* variants that occur in the canonical transcript (T260197; Ensembl genome database). All variants were annotated with the ‘non-neuro pop-max’ minor allele frequency (MAF) using the GnomAD database version v.2.1.1. Variants that were absent from GnomAD database were annotated by their MAF in the total current sample. Variants with MAF >0.05% (which relates to having at least 21 carriers in this sample) were considered less-rare. Variants with a MAF <0.05% were considered rare and included in a domain-specific rare variant burden analysis (Fig. 3).

We used the Variant Effect Predictor in Ensembl database (VEP, version v.94.542) to identify variants with a possible consequence on protein function. Missense variants were annotated with the rare exome variant ensemble learner (REVEL) score [40], which ranges from 0 (no predicted effect on protein function), to 1 (high predicted effect). Variants comprising two consecutive missense variants that give rise to two consecutive amino acid substitutions could not be annotated by REVEL and were conservatively annotated according to the substitution with the lowest REVEL score. PTVs were identified using the Loss-Of-Function Transcript Effect Estimator (LOFTEE, version v.1.0.2) [41], which annotates nonsense, frameshift and splice variants that lead to protein truncation as 1, and non-PTVs as 0. Note that PTVs in the last exon 48 should be considered deleterious, as this encodes the cytoplasmic tail domain which includes the FANSHY motif (for retromer binding), DDLGEDDED motif (sequence for binding cytoplasmic AP1 and AP2) and the DVPMV motif (sequence for GGA1 and GGA2 binding) which are all necessary for cellular trafficking and activity. Since LOFTEE did not annotate exon 48 PTVs, we manually included them in the PTV list. Splice variants with LOFTEE score 0 were evaluated using Splice AI [42] and those with a potential splice effect were evaluated manually by a trained clinical geneticist (MV), and those with expected effects on splicing were added to the list of PTVs.

**Prioritization of rare missense variants**

Rare missense variants (MAF<0.05%) were separated into high-priority variants (HPVs), moderate-priority variants (MPVs) low-priority variants (LPVs) and no-priority variants (NPVs), according to the variant prioritization scheme we developed and presented in Table 1, identified variants are listed in Table S1. HPVs were identified as according the DMDM analysis (see ‘Compendium’ in Supplementary Data for a detailed description), independent of REVEL score, and are indicated in Fig 4 and listed in Table S4. An exception is the VPS10p-domain and 10CC-domain combination, as the 5 members of the VPS10p-receptor protein family hold no/ only few known disease-associated variants. Therefore, DMDM analysis was not possible for the variants in the VPS10p-domain, such that, apart from the variants involving cysteines in VPS10p loops L1 and L2, we relied on applying a REVEL score threshold of >0.5, for which we previously found the strongest effect on AD risk [13]. MPVs are rare missense variants annotated as moderate-priority by DMDM as indicated in Fig. 4 and listed in Table S5). LPVs are rare missense variants with a REVEL score >0.5 that are not in the VPS10p-domain, and NPVs comprise all remaining rare variants that are not HPV, MPV or LPV.

**Table 1** Prioritization scheme of rare variants

Prioritization category	Selection criteria
PTV: protein truncating variants	All truncating variants: i.e. nonsense, frameshift and splice variants
HPV: High-priority missense variants	Variants that affect <i>high-priority</i> residues (Table S4) Variants in the p.VPS10p and 10CC-domains and REV0EL score $\geq 0.5^2$
MPV: Moderate-priority variants	Variants that affect <i>moderate-priority</i> residues (Table S5)
LPV: Low-priority variants	Variants <i>not prioritized</i> with REVEL score $\geq 0.50^2$
NPV: No-priority variants	All remaining variants


Rare variants with MAF<0.05%<sup>1</sup> were considered for prioritization. HPV and MPVs affect residues corresponding to the black and grey residues in Fig. 4. <sup>1</sup>MAF: Variant Minor Allele Frequency in the non-neuro pop-max dataset (Gnomad v.2.1.1). When unavailable, we used the variant MAF in the sample. Non-neuro sample in GnomAD is the sample without individuals with neurological diseases. The pop-max is the population with the highest frequency (pop-max). <sup>2</sup>REVEL (Ioannidis et al.): Variant effect prediction algorithm: Rare Exome Variant Ensemble Learner. Scores range from 0 to 1 and variants with higher scores are predicted to be more deleterious

**Rare variant association with Alzheimer’s disease**

Rare variants with a MAF<0.05% were considered in a domain-specific rare variant burden analysis (Fig. 3). We associated carrying a variant with MAF<0.05% appertaining to a specific priority category with AD (burden test). We repeated analyses stratifying EOAD cases (AD-aao<65 years) and LOAD cases (AD-aao>65 years), relative to the same group of controls. In addition to rare variants, we also analyzed less-rare variants (MAF>0.05%) (Table S2). Given the low number of carriers for many individual variants, significance of associations was assessed using Fisher’s exact test, and corrected for multiple testing (Bonferroni),  $p_{adj}<0.05$  was considered significant. All Fisher tests were performed using the epiR package (v.2.0.38). We performed additional logistic regression analyses for associations with PTV, HPV, MPV, LPV and NPV priority variant groups, adjusting for APOE genotype and population background (PC1–PC6). We could not perform these adjustments for associations with specific variant groups because sample sizes were too small.

**Age at onset curves**

Since controls were overall much younger than cases, we compared the effect of different *SORL1* variants on AAO variants in a case-only AAO analysis. We used Kaplan-Meier survival analysis (CI of 95%) to estimate AAO curves (in R using Survival (v.3.3–1). For each variant priority category, we compared the median AAO with the median AAO of *SORL1*-WT carriers in our cohort. Log rank tests were performed to test for differences between AAO curves. Additionally, we stratified according to *APOE* genotype.



**Fig. 4** Protein sequence alignments per SORL1 subdomain. The protein sequence was aligned for each repeat in each SORL1 subdomain, revealing conserved residues. Residues likely to harbor deleterious mutations based on either domain sequence conservation or because the DMDM analysis were prioritized. **Black:** High-priority variants (HPVs) affect residues annotated in black; **Grey:** Moderate-priority variants (MPVs) affect residues indicated in grey

Effect of APOE

We investigated a possible interaction-effect between *APOE* genotype (no, one or two *APOE-ε4* alleles) and *SORL1* priority category. To avoid confounding an interaction signal by samples in which *APOE* status was part of selection criteria, we performed an interaction analysis on ADES dataset only, for which there was no selection for *APOE*-genotype. We tested for both additive effect (*SORL1*+*APOE*) and interactive effect (*SORL1*\**APOE*) using a logistic regression models adjusted for PCA components (PC1–PC6). Interaction effects were tested using a Likelihood Ratio Test.

Results

After quality control we observed 637 unique coding *SORL1* variants across 18,959 genetically unrelated cases (mean age: 72.4±10.7, 59.5% females, 50.4% *APOE-ε4* carriers) and 21,893 controls (mean age: 71.1±16.7, 58.2% females, 17.2% *APOE-ε4* carriers) (Table 2).

These included 585 variants with MAF<0.05%: 74 PTVs and 511 missense variants that were further stratified into 267 NPVs, 72 LPVs, 65 MPVs, and 107 HPVs, (see Online Methods, Table S1, Fig. 3), and 52 variants with MAF>0.05% (Table S2). A summary of all association results is provided in Table 3. For groups with larger sample sizes, we performed both Fisher’s exact test and logistic regression, adjusting for principal components 1 through 6 (PC1–PC6) and *APOE* genotype, as detailed in Table S6. To assess potential population-specific differences, we conducted a sensitivity analysis comparing odds ratios between individuals of European and non-European ancestry, adjusting for ancestry principal components and *APOE* genotype (Fig S2).

PTV, protein truncating variants

The 74 PTV variants (nonsense, frameshift and splice variants), were observed in 89 cases and 6 controls (aged 49–, 53–, 64–, 75–, 80–, 85-year-old at last screening), and



Table 2 Cohort characteristics

Country	Study Cohort	Total	Total	Cases	mean AAO		EOAD	EOAD	female	APOE4-e4 genotype:		Non-EUR	Controls	mean age controls	Female	APOE4 genotype		Non-EUR
					#	QC				# (%)	#					%	hom, het, non, missing	
Germany	AgeCoDe-UKBonn	394	375	374 (99.7%)	77.5	101	27%	32%	32%	3.9%, 17.8%, 30.3%, 0%	0.30%	1 (0.2%)	73	100%	100%	0%, 100%, 0%, 0%	0.00%	
	ADES-FR	4738	4693	2567 (55%)	64.8	1569	61%	38%	38%	6%, 22.3%, 24.7%, 0%	0.50%	2126 (45%)	70.2	52%	52%	0.8%, 12.4%, 46.3%, 40.5%	0.00%	
Spain	Barcelona SPIN	80	60	51 (85%)	56.2	51	100%	55%	55%	0%, 2.9%, 47.1%, 0%	0.00%	9 (15%)	72.8	56%	56%	0%, 33.3%, 66.7%, 0%	0.00%	
The Netherlands	100-plus Study	375	347	64 (18%)	101.5	0	0%	16%	16%	0%, 7%, 43%, 0%	0.00%	283 (82%)	102.1	31%	31%	0.4%, 11%, 55.8%, 32.9%	0.40%	
	90-plus Study	103	70	0 (0%)	NA	0	NA	NA	NA	NA	NA	70 (100%)	92.2	46%	46%	0%, 10%, 82.9%, 7.1%	1.40%	
	AC-EMC	125	116	116 (100%)	59.6	92	79%	42%	42%	8%, 18.9%, 14.9%, 24.6%	4.30%	0 (0%)	NA	NA	NA	NA	NA	
	ADC-Amsterdam	1564	1145	814 (71%)	62.6	528	65%	45%	45%	9.2%, 22.5%, 22.6%, 0.6%	4.50%	331 (29%)	58.1	64%	64%	2.7%, 28.7%, 65.6%, 3%	6.30%	
	Netherlands Brain Bank	251	227	171 (75%)	73	52	30%	30%	30%	2.5%, 21.8%, 18.2%, 17.5%	0.60%	56 (25%)	81.7	45%	45%	1.8%, 21.4%, 55.4%, 21.4%	5.40%	
	ERF	1325	476	6 (1%)	NA	1	17%	33%	33%	10%, 30%, 10%, 10%	0.00%	470 (99%)	47.5	42%	42%	3.2%, 28.1%, 66.4%, 2.3%	0.20%	
	Rotterdam Study	2699	1931	378 (20%)	83.5	1	0%	31%	31%	3.5%, 19.1%, 28.7%, 1%	0.30%	1553 (80%)	82.7	44%	44%	1.4%, 24.2%, 71.7%, 2.7%	0.30%	
	UMC-Amsterdam	6930	5632	164 (3%)	59.4	133	81%	47%	47%	12.1%, 25.3%, 18%, 1.4%	7.30%	5468 (97%)	45.2	61%	61%	0.1%, 0.3%, 0.5%, 99.2%	19.40%	
United Kingdom	CBC	471	390	130 (33%)	NA	39	30%	45%	45%	5.3%, 26.8%, 20.3%, 0.4%	1.50%	260 (67%)	75.8	60%	60%	1.5%, 26.5%, 50.8%, 21.2%	1.20%	
	PERADES	4936	4335	3633 (84%)	69.5	1357	37%	42%	42%	4.3%, 18.4%, 20.4%, 18.2%	0.20%	702 (16%)	81.5	42%	42%	1.7%, 16.4%, 64.5%, 17.4%	0.00%	
	UCL-DRCEOAD	539	466	466 (100%)	NA	437	94%	45%	45%	6.8%, 17.8%, 27.9%, 1.9%	6.20%	0 (0%)	NA	NA	NA	NA	NA	
USA	ADSP	25798	18963	8979 (47%)	75.9	1180	13%	40%	40%	3.3%, 21.2%, 27.1%, 0.1%	28.70%	9984 (53%)	80.9	36%	36%	1.1%, 21.7%, 77.2%, 0.1%	41.40%	
	Knight-ADRC*	1039	1038	658 (63%)	69	275	42%	47%	47%	9.1%, 28.5%, 16.8%, 0.3%	0.00%	380 (37%)	76.7	44%	44%	4.2%, 33.9%, 61.1%, 0.8%	0.00%	
	StEP-AD*	278	278	173 (62%)	57.3	171	99%	50%	50%	1.8%, 4.1%, 45%, 0%	0.00%	105 (38%)	79.6	42%	42%	26.7%, 61.9%, 11.4%, 0%	0.00%	

Table 2 (continued)

Country	Study Cohort	Total	Total	Cases	mean AAO	EOAD	EOAD	female	APOE4-e4 genotype:	Non-EUR	Controls	mean age controls	Female	APOE4 genotype	Non-EUR
		#	# QC	# (%)		#	%	%	hom, het, non, missing	%	# (%)		%	hom, het, non, missing	%
	UCSF/NYGC/UAB	736	310	215 (69%)	59.5	168	78%	48%	8.3%, 22.7%, 23.2%, 0%	8.40%	95 (31%)	69.4	39%	2.1%, 21.1%, 76.8%, 0%	6.30%
	TOTAL	52,361	40,852	18,959 (46%)	71.4	6,155	32%	40%	4.5%, 20.8%, 25.2%, 3.5%	14.20%	21,893 (54%)	72.7	41%	1.1%, 16%, 52.6%, 30.4%	23.90%

Characteristics of the samples contributed by each study, grouped by country. Sequencing is based on exome sequencing, except for UCS/NYGC/UAB, which was based on whole genome sequencing (WGS) data. Respectively 11 and 10% of the ADSP AD cases and controls comprised WGS data, and 30% of the ADES-FR cases. QC: quality control; next to selection based on technical procedures as described in the Online Methods, we included only genetically unrelated individuals (Identity By Descent > 3<sup>rd</sup> degree relations). A.A.O: mean age at onset; A.L.S: mean age at last screening. EOAD: early onset cases, a.a.o. ≤ 65. Ages annotated ">89" were set to 90. See supplement for detailed cohort descriptions. Non-Europeans: Africans (AFR), Admixed Americans (AMR), East Asians (EAS), and South Asians (SAS). \*Samples from Knight-ADRC and StEP-AD cohorts were extracts of the coding sequences of the *SORL1*, *TREM2*, *ABCA7*, *ATP8B4*, *ABCA1*, *ADAM10*, *RIM3*, *CLU*, *ZCWPW1*, *ACE*, and *CBX3* genes as described previously [13], and based on a separate PCA on these extracts, samples were annotated as EUR as we did not identify population outliers based on these exome extracts. To distinguish non-Europeans from Europeans (Table 2) we trained a k-nearest neighbor classifier on the first 10 PCA components, using the 1000 G samples (SKLearn 26 v0.20.3, k = 10)

associated with an overall 17.2-fold increased risk of AD (95%CI 7.5–39.3;  $p=1.2\times10^{-21}$ ). PTVs associated with a 35.3-fold increased risk of EOAD (95%CI 15.2–81.8;  $p=6.2\times10^{-31}$ ) and an 8.6-fold increased risk of LOAD (95%CI 3.6–20.6;  $p=3.8\times10^{-7}$ ) (Table 3). A survival analysis indicated that the median AAO of a *SORL1*-PTV carrier was 62 years (10%-90% range: 52–78), 10-years earlier (95%CI –12– –8;  $2.7\times10^{-11}$ ) than the median AAO of *SORL1*-wild-type (WT) carriers in our sample at 72 (10%-90% range: 56–87) (Fig. 5A, Table 3).

HPV, high-priority missense variants

The 107 HPVs were carried by 151 AD cases and 29 controls, and these associated with an overall 6.1-fold increased risk of AD (95%CI: 4.1–9.0,  $p=5.3\times10^{-24}$ ). Specifically, HPVs associated with a 9.9-fold increased risk of EOAD (95%CI: 6.5–15.2,  $p=7.8\times10^{-29}$ ), and to a 4.2-fold increased risk of LOAD (95%CI 2.7–6.5;  $p=1.3\times10^{-10}$ ) (Table 3). Of the 107 HPVs, 77 (72%) were singletons (66/77 in AD cases), we observed 18 HPVs in two individuals (30/36 were AD cases), 12 variants in ≥ 3 individuals, and one variant (p.Y391C) in 12 individuals in the sample (all AD cases). The median AAO of HPV-carriers was 64 years (10%-90% range: 53–79), 8 years (95%CI –10– –6;  $5.3\times10^{-9}$ ) earlier than *SORL1* WT AD cases (Fig. 5A, Table S7).

VPS10p-domain (res 82–617) and 10CC-domain (res 618–753)

The 27 HPVs in the VPS10p-domain associate with overall 8.8-fold increased risk of AD (95%CI 3.5–22.3;  $p=3.4\times10^{-7}$ ); with a 15.7-fold increased risk of EOAD (95%CI 5.9–41.5;  $p=2.2\times10^{-9}$ ) and a 5.5-fold increased risk of LOAD (95%CI: 2.0–15.0;  $p=9.5\times10^{-3}$ ) (Table 3). We identified 6 HPVs involving cysteines in the L1 or L2 loops, which are involved in ligand-binding and unique to the VPS10p-domain of *SORL1* [44]. Intriguingly, 12 unrelated AD cases (no controls) gained a cysteine in L1 (p.Y391C), suggesting that this variant is highly penetrant. Carriers had a median AAO of 67.5 years, which was 5.5 years later compared to PTV carriers, but 4.5 years earlier than *SORL1* WT carriers (Fig. 5B, Table S7). One control (aged 45) gained a cysteine in L1 (p.G398C), two cases lost, and two cases gained a cysteine in L2 (C467Y, C473S and twice R480C), and one control (aged 71) gained a cysteine in L1 (p.G398C, aged 45) or L2 (p.S474C, aged 71). We further identified 16 HPVs with a REVEL score ≥ 0.50, carried by 16 cases and 3 controls, which in aggregate had an AAO of 2.5 years earlier than PTV-carriers (95%CI: –4–13) and 12.5 years earlier than *SORL1* WT carriers (Fig. 5B, Table S7). Of particular interest are the four variants that affect the Asp-box, that stabilizes the β-propeller by forming interactions between propeller blades, with the L1/L2 loops and with

**Table 3** Effect of variant subtypes on AD risk, and effect on age at onset

Variant ID/ type	Variant Subcategory	Variant effect on AD risk				Effect on AAO						
		carriers		# unique variants		Me- dian AAO	Δ AAO vs WT	p value*				
		all/EOAD/LOAD/controls	carriers	all/EOAD/LOAD/controls	carriers							
domain residues	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls				
OR	p value	OR	p value	OR	p value	OR	p value	OR				
SORL1 WT												
WT	N/A	31,324/4,642/9,677/17,005	N/A	0.89 (0.85 -0.93)	8,68E-06	0.88 (0.83 -0.94)	6.20E-03	0.89 (0.85 -0.94)	2.30E-04	72 (56 -87)	NA	N/A
Non-rare variants, MAF > 0.05%												
E270K*	VP510p, β4 strand, pos 35	1,409/212/479/718	1/1/1/1	1.02 (0.92 -1.13)	6.88E-01	0.94 (0.81 -1.1)	4.30E-01	1.1 (0.95 -1.2)	2.90E-01	72 (56 -87)	0 (-1—0)	1
A528I*	VP510p, β8 strand, pos 47	2,719/495/961/1,263	1/1/1/1	1.2 (1.08 -1.26)	6.15E-05	1.1 (1.03 -1.27)	1.20E-02	1.2 (1.08 -1.28)	1.6 E-04	71 (55 -86)	-1 (-2—-1)	1.70E-01
D2065V*	3Fn6, pos 47	353/55/106/192	1/1/1/1	0.9 (0.7 -1.07)	1.79E-01	0.87 (0.64 -1.18)	3.70E-01	0.9 (0.68 -1.09)	2.20E-01	70 (53.1 -85)	-2 (-4—-1)	7.10E-01
All other	N/A	4,035/500/1,314/2,221	48/34/38/45	1.0 (0.95 -1.09)	6.00E-01	1.0 (0.91—1.12)	8.20E-01	1.0 (0.95 -1.10)	6.40E-01	74 (57 -87)	2 (-1—1)	1
Rare Missense variants												
NPV: no priority	N/A	612/101/199/312	267/75/135/158	1.1 (0.9 -1.3)	1	1.2 (0.9 -1.4)	1	1.1 (0.9 -1.3)	1	73 (55 -86)	1 (-1—1)	1
LPV: low priority	N/A	170/33/52/85	72/22/32/46	1.2 (0.9 -1.6)	1	1.4 (0.9 -2.1)	1	1.0 (0.7 -1.5)	1	70 (56— 84.9)	2 (-5 - 2)	1
MPV: Moder- ate priority	N/A	141/20/60/61	65/16/39/33	1.5 (1.1 -2.1)	3.90E-01	1.2 (0.7 -1.9)	1	1.7 (1.2 -2.4)	1.20E-01	72 (54 -86)	0 (-1—1)	1
HPV: high priority	N/A	180/80/71/29	107/62/50/23	6.1 (4.1 -9.0)	5.30E-24	9.9 (6.5 -15.2)	7.80E-29	4.2 (2.7 -6.5)	1.30E-10	64 (53 -79)	-8 (-10—-6)	5.30E-09
PTV: protein truncating	N/A	95/59/30/6	74/52/25/6	17.2 (7.5 -39.3)	1.20E-21	35.3 (15.2 -81.8)	6.20E-31	8.6 (3.6 -20.6)	3.80E-07	62 (52 -78)	-10 (-12—-8)	2.70E-11
HPVs per domain												
VP510p domain	Total	43/22/16/5	27/17/10/5	8.8 (3.5 -22.3)	3.40E-07	15.7 (5.9 -41.5)	2.20E-09	5.5 (2.0 -15)	9.50E-03			
Cysteins gained & cysteins lost		18/8/8/2	6/4/2/2	9.2 (2.1 -40.2)	6.70E-03	14.2 (3.0 -67.1)	4.50E-03	6.8 (1.5 -32.2)	1.90E-01			
L1/L2												
Asp-box, REVEL > 0.5		6/3/3/0	5/3/3/0	NA	2.80E-01	NA	3.00E-01	NA	1			

Variant ID/ type	Variant Subcategory	# unique variants						Variant effect on AD risk				Effect on AAO				
		carriers						All carriers		EOAD		LOAD		Me- dian AAO	$\Delta$ AAO vs WT	p value*
		domain residues	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	all/EOAD/LOAD/controls	All carriers	EOAD	LOAD	LOAD							
								OR	p value	OR	p value	OR	p value	(10%- 90% IPR)	(95% CI)	
10CC domain	Remaining p.VPS10p variants, REVEL > 0.5	19/11/5/3	16/10/5/3	6.2 (1.8 - 21.2)	2.60E-02	13.1 (3.6 - 46.8)	2.80E-04	2.9 (0.7 - 11.9)	1	59.5 (46 - 83)	-12.5 (-16--5)	1				
	Total	30/11/13/6	19/8/10/3	4.6 (1.9 - 11.3)	8.70E-03	6.5 (2.4 - 17.7)	5.00E-03	3.7 (1.4 - 9.8)	1.90E-01	67 (57 - 78)	-5 (-9--0)	1				
	Total	25/13/7/5	12/9/6/5	4.6 (1.7 - 12.3)	2.60E-02	9.3 (3.3 - 26.0)	2.10E-04	2.4 (0.8 - 7.5)	1							
	<b>YWTD-motif (17, 18, 19, 20)</b>	8/6/2/0	6/5/2/0	NA	6.20E-02	NA	3.10E-03	NA	1	64 (44 - 68)	-8 (-24--NA)	2.50E-03				
EGF domain	Highly conserved residues (29, 35)	8/2/3/3	3/2/2/3	1.9 (0.5 - 8.1)	1	2.374(0.4 - 14.2)	1	1.7 (0.4 - 8.5)	1							
	partly conserved residues (9,38)	8/4/2/2	2/1/2/2	3.5 (0.7 - 17.2)	1	7.1 (1.3 - 38.9)	6.70E-01	1.71(0.2 - 12.1)	1							
	Cysteines gained or lost	2/1/0/1	2/1/0/1	1.15 (0.1 - 18.5)	1	3.6 (0.2 - 56.9)	1	NA	1							
	Total	57/23/26/8	36/21/19/6	7.1 (3.4 - 15.0)	1.90E-08	10.3 (4.6 - 23.0)	2.30E-08	5.6 (2.5 - 12.3)	8.60E-05							
CR domain	<b>Calcium Cages (D, D, D, E) 37, 41, 47, 48</b>	13/9/4/0	12/9/4/0	NA	1.30E-03	NA	3.40E-05	NA	5.10E-01	60 (54 - 73)	-12 (-16--NA)	7.70E-04				
	Cysteines gained or lost	42/12/22/8	22/10/15/6	4.9 (2.3 - 10.6)	1.80E-04	5.3 (2.2 - 13.1)	7.30E-03	4.7 (2.1 - 11.0)	2.00E-03	68 (53 - 82)	-4 (-9--1.3)	1				
	Asx-turn (D) (44)	2/2/0/0	2/2/0/0	NA	1	NA	1	NA	NA							
	Total	15/8/5/2	10/5/4/2	7.5 (1.7 - 33.3)	7.80E-02	14.2 (3.0 - 67.1)	4.50E-03	4.3 (0.8 - 22.0)	1							
Fn domain	Partly conserved glycines (36, 96)	2/1/1/0	2/1/1/0	NA	1	NA	1	NA	1							



Table 3 (continued)

Variant ID/ type	Variant Subcategory	carriers	# unique variants	Variant effect on AD risk						Effect on AAO		
				domain residues	all/EOAD/LOAD/controls		EOAD		LOAD	LOAD	p value	p value*
					All carriers	OR	p value	OR				
				all/EOAD/LOAD/controls	OR	p value	OR	p value	(10%- 90% IPR)	(95% CI)		
	Partly conserved prolines (6, 7, 79)	4/2/2/0	4/2/2/0	NA	1	NA	1	NA	1			
	highly con- served residues (25,41,77, 83)	9/5/2/2	4/2/1/2	4.0 (0.8 - 19.5)	1	8.9 (1.7 - 45.9)	2.00E-01	1.7 (0.2 - 12.1)	1			

AAO: Age at onset; OR: odds ratio, calculated using a Fisher's Exact test. Note that all effect sizes were calculated relative to the same control group, which was relatively young, such that effect sizes may be conservative.  $\rho$ : Odds ratios for all variants with  $\text{MAF} > 0.05\%$  were calculated using a logistic regression model on the minor allele dosages,  $p$  values were corrected for multiple testing using Bonferroni. All other variants were also imputed in the latest GWAS [43] (Table S2), association statistics for the most common variants were: E270K:  $p = 5.89 \times 10^{-11}$ ; A528T:  $\text{OR} = 1.07$ ,  $p = 5.79 \times 10^{-8}$ . For the 22065V variant we observed an  $\text{OR} = 1.36$  (95%CI 1.2–1.54) with a  $p$  value =  $1.61 \times 10^{-6}$ , which is in the opposite direction compared to the AD association observed in the current exome sequencing dataset ( $\text{OR} = 0.87$ ,  $p = 0.18$ ).  $\rho$  value. Possibly, effects may be weaker in ECAD cases, which are more prevalent in the exome study compared to the GWAS study.


the nearby 10CC-domains: three cases with p.S564G, p.T570I or p.S138F, and two cases with p.D236G. The 10CC-domain, C-terminal to the VPS10p-domain, stabilizes VPS10p  $\beta$ -propeller, and losing one of the 10 highly conserved cysteines or gaining a cysteine will likely impair domain folding. One case carried p.C716W, and two cases carried p.Y722C. In aggregate, we observed 19 variants affecting the 10CC-domain, with a median AAO of 67 years, 5 years earlier than *SORL1* WT carriers (Fig. 5B, Table S7).

**YWTD-domain (res 754–1013) and EGF-domain (res 1014–1074)**

We identified 6 HPVs that affect the highly conserved YWTD-motif, which maintains the structural and functional integrity of the  $\beta$ -propeller. These were carried by 8 AD cases, with an AAO of 8 years earlier than *SORL1* WT carriers (Fig. 5B, Table S7). Five cases (AAO 46–78) and one control carried the deleterious p.R953H variant, substituting a positively charged arginine at position 38 in the 5<sup>th</sup> blade of the YWTD-domain (see ‘Compendium’ in Supplementary Data). The EGF-domain includes eight cysteines that likely form four intradomain disulfide-bridges to stabilize the EGF:YWTD  $\beta$ -propeller unit (Fig. 1). One case carried a p.Y1064C substitution and one control carried a p.C1026R substitution. Taken together, carrying a variant affecting the YWTD-domain leads to a 4.6-fold increased risk of AD (Table 3).

**CR-domain (res 1075–1550): calcium-cage and cysteines**

13 cases and no controls carried 12 unique variants affecting calcium-cage residues (one variant observed in two individuals), suggesting high penetrance. The median AAO of carriers was 12 years earlier than *SORL1* WT cases, and 2 years earlier compared to PTVs carriers. (Fig. 5B, Table S7). One calcium-cage variant, p.D1108N, affecting the 1<sup>st</sup> CR-domain, was observed in three unrelated AD cases (AAO 73, 69 and 54). Another case (*APOE*- $\epsilon$ 3/ $\epsilon$ 3, AAO 66) carried two calcium-cage variants, p.D1261G in the 5<sup>th</sup> CR-domain and p.D1345N in the 7<sup>th</sup> CR-domain; due to the distance between them on DNA level (~3kb) we could not determine whether these variants were *in cis* or *in trans*. Furthermore, a disruption of the conserved pattern of 6 cysteines (odd number of cysteines, ONC) impairs CR-domain folding and leads to dysfunctional SORL1 protein. We identified 15 cysteine-gained and 7 cysteine-lost variants carried by 34 cases and 8 controls: such that carrying an ONC variant associates with a 4.9-fold increased risk of AD (95%CI: 2.3–10.6;  $p = 1.8 \times 10^{-4}$ ) (Table 3). Among the genetically unrelated individuals, we observed p.R1490C in five cases and two controls, p.R1080C in four cases, p.R1124C in three cases and one control. The median AAO of ONC-carriers was 68 years, 4 years earlier than *SORL1*



**Fig. 5** Age at onset analysis of case-carriers. AD cases were categorized according to the variant subtype they carry. **(A)** Age at onset analysis for carriers of missense variants annotated as high-, moderate-, low- and no-priority, compared to carriers of PTVs and SORL1 WT carriers. **(B)** Age at onset analysis of carriers of specific high-priority missense variants, relative to carriers of PTVs and WTs. **(C)** Age at onset analysis of less rare variants (MAF > 0.05%). Horizontal lines indicate the age at which 50% of all carriers with the same variant category have AD. Differences in ages at onset between carriers of variants appertaining to specific variant-groups are shown in Table S7

WT-carriers, and 6-years *later* than PTV-carriers (Fig. 5B, Table S7). One case (*APOE-ε3/ε4*, AAO 46) carried a p.C1453F ONC variant in combination with a PTV: variants were too far apart to confirm whether they were *in-cis* or *in-trans*.

### 3Fn-domain (res 1551–2121)

Disturbing domain-stabilizing interaction between the leucine at domain-position 77, a proline at position 79, and a tyrosine at position 83 ('tyrosine corner') critically impairs SORL1 dimerization [19]. Six unrelated cases carried a p.Y1816C (position 83, average AAO 60.2 years), one case carried p.P1619Q (position 79, AAO 59 years). One 45-year-old control carried p.L1617V (position 77): given the importance of the tyrosine corner in SORL1 function, it is not unlikely that this individual will develop AD at a later age. Conserved glycines at positions 36 and 96 may affect domain stability or ligand binding: we identified one case with a p.G1732A (position 96) with AAO at 70 years and one case (*APOE-ε2/ε4*) with a p.G1681D (position 36) with AAO 46 years. Notably, the pathogenicity of the p.G1732A variant is also supported by Thonberg et al. [17]. Lastly, four cases and one control carried variants affecting the residues that contribute to the hydrophobic core of the 3Fn-domain, which acts as the 'glue' that connects the two β-sheets that constitute the 3Fn-domain sandwich (tryptophan at position 25 and the tyrosine at position 41). Furthermore, substitution of the moderate-priority prolines at positions 6, and 7 that occur in some 3Fn-domains were observed only in cases.

### Transmembrane and tail domain (res 2161–2214)


There were no variants prioritized in these domains.

### Effect of *APOE-ε4* allele


In the dataset (excluding the ADSP cohort, methods) AD risk increases 3-fold for each added *APOE-ε4* allele (95%CI 2.8–3.2,  $p = 1.3 \times 10^{-221}$ ). The median AAO for

*APOE-ε4/ε4* AD cases was 64 years for those wild-type for *SORL1* (10%-90% range: 54–77), 60 years for PTV-carriers (10%-90% range: 53–65), and 58.5 years for HPV-carriers (10%-90% range: 53–69). The median AAO for *APOE-ε4* heterozygous AD cases was 70 years for those wild-type for *SORL1* (10%-90% range: 55–82), 61 years for PTV-carriers (10%-90% range: 51–74), and 63 years for HPV-carriers (10%-90% range: 54–78). The median AAO *APOE-ε4*-negative AD cases was 75 years for those wild-type for *SORL1* (10%-90% range: 56–89), 69 years for PTV-carriers (10%-90% range: 52–81), and 66 years for HPV carriers (10%-90% range: 48–86) (Fig. 6, Table S8). Together, carrying a *SORL1* PTV or HPV expedited AAO by respectively 6 years (95%CI –10– –2) and 9 years (95%CI –13– –1.7) for *APOE-ε4*-negative AD cases, by respectively 9 (95%CI –10– –6) and 7 (95%CI –8– –4) years for *APOE-ε4*-heterozygous cases, and by respectively 4 (95%CI –6–NA) and 5.5 (95%CI –8–NA) years for *APOE-ε4/ε4* cases. This indicates a major additive effect of *APOE* genotype. Evidence for an interactive effect in PTV- and HPV-carriers was limited ( $p = 0.04$  and  $p = 0.06$  respectively). However, inferences regarding a possible interaction effect may be incorrect as this case/control analysis design lacks power: only 18 controls with known *APOE* genotype carried a PTV or HPV, of whom 15 were negative for the  $\epsilon 4$  allele (83%). Also, 5 were younger than 65 (28%) such that future AD is not unlikely in variant carriers. Nevertheless, the additive and possibly synergistic effect of *APOE-ε4* allele explains, in part, the variability in AAO of carriers of the same variant. The AAO-range of the twelve Y391C cases was 60–86 years, 56–91 years for five p.R744RX carriers, 60–73 years for four p.R866X carriers, 46–78 years for p.R953H carriers, and 56–74 for six p.Y1816C carriers (Fig S4). Indeed, EOAD cases were more likely to carry at least one *APOE-ε4* allele, while older cases often carried a protective *APOE-ε2* allele (Fig S5). There was no

## A: Protein Truncating Variants



## B: High priority missense variants



**Fig. 6** Rare *SORL1* variants in context of APOE genotype. **(A)** AD cases who carried PTV in *SORL1* have an earlier age at onset compared to *SORL1* WT carriers with the same APOE genotype. The orange ages indicate at what age respectively 50% of the variant carriers had AD, the black ages indicate at the age at which 50% of the *SORL1* WT carriers developed AD. **(B)** High-priority variants in context of APOE genotype. carriers of a high-priority variant have an earlier age at onset compared to wildtype carriers with similar APOE genotype. The effects of MPVs, LPVs and NPVs in context of APOE is shown in Fig S3

significant difference in the distribution of APOE- $\epsilon 4$  carriers between PTV and HPV groups ( $p = 0.31$ , chi-squared test).

### MPVs, LPVs, NPVs and variants with MAF > 0.05%

MPVs, LPVs and NPVs had no or negligible effects on AD (Fig. 5A, Table 3) and there was no change in AAO relative to *SORL1* WT cases (Fig. 5C). Likewise, the most common coding *SORL1* variants p.A528T and p.E270K with sample-MAFs of respectively 3.6% and 1.9%, are associated with a 1.1-fold and 1.0-fold increased risk of AD when imputed in GWAS [43]. For p.D2065V, with

sample-MAF 0.46%, we observed a 1.4-fold increased AD risk, and carriers had a slightly expedited AAO relative to *SORL1* WT cases (Fig. 5C). See ‘1.2 Effects of non-HPV and non-PTV rare *SORL1* variants’ in the Supplement for a more in-depth analyses of these variants.

### Comparison of prioritization scheme vs using only REVEL scores or AlphaMissense

While in aggregate, the 107 HPVs prioritized by DMDM, associated with a 6.1-fold increased risk of AD (i.e EAOD and LOAD combined), the aggregate of variants with a REVEL [40] or the AI-based AlphaMissense [45]

score > 0.9 (both with score range 0–1) was associated respectively with a 3.9-fold (95%CI 1.9–8.0) and 3.5-fold (95%CI 2.1–5.5) increased risk of AD (Fig S6). This suggests that there is added value in combining in silico or AI-based prediction tools with manual variant annotation based on years of expertise.

## Discussion

In our assembled sample of 18,959 AD cases and 21,893 controls we identified 107 rare missense variants with  $MAF < 0.05\%$  as ‘high-priority’ HPV after applying a manual DMDM analysis. HPVs are associated with a 6-fold increased risk of overall AD (EOAD and LOAD combined), and 10-fold increased risk of EOAD. In this sample, the carriers of such variants had a median AAO of 64 years, 8 years earlier than carriers of wild-type *SORL1*. In comparison, carrying a PTV associated with an overall 17-fold increased risk of overall AD relative to non-carriers, and a 35-fold increased risk of EOAD. *SORL1* PTV-carriers in this sample had a median AAO of 62 years, 10 years earlier than carriers of wild-type *SORL1*. Other rare missense variants with  $MAF < 0.05\%$ , or coding variants with  $MAF > 0.05\%$  had no or only limited effects on AD risk.

Although the median AAO of *SORL1* PTV or HPV-carriers indicates a predisposition for EOAD, AAO is several years later than for carriers of established pathogenic variants in the *PSEN1*, *APP*, and *PSEN2* ADAD genes, with average AAO respectively ~45, ~50 years and ~55 years [46–48]. Akin to observations in established ADAD, we observe an additive (and possibly synergistic) effect of *APOE* genotype on AAO of *SORL1* PTV and HPV-carriers [49, 50]. The median AAOs for PTV and HPV-carriers who are  $\epsilon 4/\epsilon 4$ ,  $\epsilon 4$ -heterozygous or  $\epsilon 4$ -negative are respectively 60, 61 and 69 years and 58.5, 63 and 66 years, which is in agreement with a report stating that penetrance for *SORL1*-PTV and HPV-carriers combined was complete by age 70 among  $\epsilon 4/\epsilon 4$  carriers, 10 years later for  $\epsilon 4$ -heterozygous carriers and even later for non- $\epsilon 4$  variant-carriers [14]. In addition to the *APOE* genotype, other genetic risk factors will further influence AAO, akin to observations in established ADAD [43, 46, 50].

On average, HPVs and PTVs have a similar AAO. However, when grouping variants based on affected residues, certain HPVs have an earlier AAO than PTVs, while others have a later AAO. Variants that affect a calcium-cage residue in one of the CR-domains [51, 52], the YWTD-motif or the VPS10p-domain had an *earlier* AAO than carriers of PTV variants, suggesting they might have a dominant negative effect. Notably, variants affecting the YWTD-motif or a calcium-cage were observed only in AD cases, indicative of high penetrance. A dominant negative effect may be explained by requirement

for *SORL1* to dimerize (or possibly polymerize) at its 3FN-domains, before docking into the retromer [1, 31]. Variants that lead to impaired protein folding cannot be properly matured at the endoplasmic reticulum (ER) [53], such that the receptor cannot exit the ER. However, so long as the 3FN-domains remain in-tact, any mutant *SORL1* will retain the propensity to dimerize while still in the ER, not only with other mutant-*SORL1*, but also WT-*SORL1*. This way, *less* than half of *SORL1* protein can exit the ER to perform its cargo trafficking functions. This mode of pathogenicity may also explain the (familial) AD observed for the carriers of the p.R953H and the p.R953C ‘Seattle variant’ affecting YWTD-domain folding, for which functional studies have shown impaired trafficking [20], and the p.G511R variant, suggesting impaired binding of Amyloid- $\beta$  to *SORL1* [44, 54].

ER-retention prevents *SORL1* protein to traffic to the cell surface, such that these variants will likely lead to decreased shedding of soluble *SORL1* (s*SORL1*) in the interstitial space, as shown for the p.D1105H variant [55]. We acknowledge that the earlier AAO of these specific *SORL1* missense variants relative to PTVs concerns only few carriers, such that statistical significance cannot be reached. Therefore, the associated dominant negative effects need to be confirmed in an independent large sequencing dataset of AD cases and controls and/or by further functional studies.

The effect on AAO of other HPVs may be similar to the haploinsufficiency associated with PTVs. An example is the p.Y1816C mutant that affects the ‘tyrosine corner’, a residue that contributes strongly to the stability of 3<sup>rd</sup> 3Fn-domain which was carried by the probands and affected family members of three unrelated pedigrees [19]. Functional experiments indicated that the p.Y1816C mutant is efficiently matured and trafficked from the ER to the endosome. Once there, it fails to form the dimer-dependent complex with retromer, such that the *SORL1* mutant cannot contribute to retromer sorting. However, the wild type allele still can, suggesting that the variant leads to haploinsufficiency. We observed that s*SORL1* levels were substantially reduced in a carrier of this variant, mimicking the effect we observe for PTVs on s*SORL1* shedding [56]. This mode of pathogenicity may also apply to the p.G1732A variant, likely impairing the folding of the 2<sup>nd</sup> 3Fn-domain, which was identified in a pedigree affected with EOAD [17].

Other HPVs lead to a slightly *later* AAO than PTV variant carriers, suggesting that their effects are less damaging than losing one *SORL1* copy. We speculate that the p.Y391C substitution affecting Loop L1 in the VPS10p-domain (observed in 12 cases) affects ligand-binding of the VPS10p-domain, leading to decreased lysosomal delivery of (among other ligands) Amyloid- $\beta$  and to an increase of secreted Amyloid- $\beta$  [54]. However, other



SORL1 functions may still be in-tact, which may explain a less deleterious effect compared to carrying a PTV. Carriers of variants affecting the 10CC-domain, or that lead to losing or gaining a cysteine in the CR-domain also have a later AAO compared to PTV carriers, suggesting some residual activity for these mutants. These variants may lead to an unstable receptor, some of which may be removed by the ER-associated degradation pathway, while others may escape the ER control-check and be exported to subsequent cellular compartments. While we cannot provide any supporting evidence at current, this mode of pathogenicity might explain the EOAD observed for carriers of the p.R1303C substitution (cysteine-loss in the 6<sup>th</sup> CR-domain), in one of the pedigrees described by Thonberg et al. [17]. Additional functional evidence is necessary to support the different modes of pathogenicity associated with different HPV-types.

Ideally, risk and AAO analysis are assessed in population-based follow-up studies. However, genetic variants associated with EOAD are extremely rare, such that sequencing all individuals from a population study will not yield informative data. Therefore, our dataset is an assembled sample of AD cases and controls which is relatively enriched with EOAD cases. The effect of this enrichment is observable in the earlier median AAO of AD cases that are homozygous, heterozygous or negative for the *APOE-ε4* allele (respectively 64, 70 and 75 years) compared to a population sample (70, 74.5, 82 years, as estimated from Reiman et al. [57]). We acknowledge that determining odds ratios for EOAD and LOAD separately only partly accounts for the influence of age on the effect of *SORL1* variants on AD risk. Note also, that all effect sizes were calculated relative to the same control group and that at the time of sample inclusion, 50% of the controls was younger than 65 (33% was even younger than 50), making it likely that some controls may develop AD at a later age, such that effect sizes presented here may be conservative. On the other hand, recent analyses have indicated that within a pedigree, the AAO of the index patient was significantly earlier than those of family-members [14]. We suspect that our sample of genetically unrelated individuals may be enriched with index patients, which may skew the distribution towards relatively early AAO. Nevertheless, it is valid to compare effects on AD risk and AAO distributions between the different *SORL1* variants *within* our sample, as similar biases apply to all other AD cases and controls. Overall, we caution that AAO distributions and effects on AD risk are not representative of the overall population.

Several *SORL1*-features may be considered when investigating *SORL1* variants. Exons 23–33 each translate one CR-domain, such that exon-skipping splice-variants may translate to a *SORL1* protein lacking one CR-domain. It is unclear whether this yields an inactive or (partly) active

*SORL1* [58]. An exception is the 7<sup>th</sup> CR-domain, encoded by exon 29, since joining exons 28 and 30 produces a nonsense-codon. Exon 1 was excluded from analysis due to differential missingness, however upon inspection we identified 9 PTVs in exon 1, of which 4 in controls, while PTVs in the rest of the gene occurred almost exclusively in AD cases. Although we cannot provide supporting evidence to substantiate this, the use of an alternative transcriptional start site, which could allow escape from nonsense-mediated decay, may be a back-up mechanism for *SORL1* transcription [59]. Furthermore, it is unclear whether variants observed in several genetically unrelated individuals share a founder mutation: p.Y391C (12 cases), p.R1490C (5 cases/2 controls), p.Y1816C (6 cases), p.R953H (6 cases/1 control), p.R744X (5 cases) and p.R866X (4 cases). If these variants occurred *de novo* in each pedigree this might provide preliminary evidence for mutation hotspots in *SORL1*.

## Conclusion

Here, we show that carriers of *SORL1* PTVs and HPVs have diverse AAOs, which are influenced by *APOE* genotype, complicating penetrance estimates [14, 60]. This is in parallel with variants in genes implicated in hereditary breast cancer including the ‘high risk’ genes *BRCA1*, *BRCA2*, and *PALB2* and ‘moderate risk’ genes *CHEK2* and *ATM* [61]. In all these genes, PTVs generally associate strongest with disease risk while missense variants have variable effects and are notoriously more difficult to classify. The oncogenetics field has created specific guidelines for testing and counseling high- and moderate risk genes [62], which may be explained by the actionability of oncogenes (e.g., screening programs or preventive surgery). In the absence of actionability, the AD field has historically been more hesitant to adopt genetic testing of genes for which variants that segregate with AD across multiple generations have not yet been identified. Nevertheless, some historically high-risk genes for neurodegenerative disorders, such as variants in *NOTCH3* that cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), are now considered a spectrum of high and moderate risk conferring variants, and they are counseled accordingly. Here, we show that a subset of *SORL1* variants is highly penetrant for AD with an AAO that overlaps with that observed for carriers of known pathogenic variants in *PSEN2* [23] and even some variants in *PSEN1* [63]. With actionability of Alzheimer’s Disease on the horizon, our results encourage engaging a discussion on whether reporting these variants to patient-carriers is desirable, possibly in combination with *APOE* genotype.

## Abbreviations

AAO	Age at onset
AD	Alzheimer’s disease

ADAD	Autosomal dominant Alzheimer's disease
APP	Amyloid precursor protein
DMDM	Domain-mapping of disease mutations
EOAD	Early onset Alzheimer's disease
ER	Endoplasmic Reticulum
GWAS	Genome wide association Studies
HPV	High priority variant
LOAD	Late onset Alzheimer's disease
LPV	Low priority variant
MAF	Minor allele frequency
MPV	Moderate priority variant
NPV	No priority variant
ONC	Odd number Cysteines
PCA	Principal Component Analysis
PTV	Protein truncating variants
REVEL	Rare exome variant ensemble learner
VEP	Variant effect predictor
VUS	Variant of unknown significance
WES	Whole exome sequencing
WGS	Whole genome sequencing
WT	Wild-type

## Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1186/s13024-025-00907-z>.

Supplementary Material 1

Supplementary Material 2

## Acknowledgements

The authors are grateful to all study participants, their family members, the participating medical staff, general practitioners, pharmacists and all laboratory personnel involved in patient diagnosis, blood collection, blood biobanking, DNA preparation and sequencing. We further acknowledge the collaborative support of the Alzforum, specifically Elizabeth Wu and Kathleen Zahs in this work, for critical feedback of the prioritization approach and for making all variants available on the Alzforum SORL1 database (<https://www.alzforum.org/mutations/sorl1>). The data used in this work was collected using the funding obtained by the following study cohorts: ADES-FR, AgeCoDe-UKBonn; Barcelona SPIN; AC-EMC; ERF and Rotterdam; ADC-Amsterdam; 100-plus study; EMIF-90+; Control Brain Consortium; PERADES; StEP-AD; Knight-ADRC; UCSF/NYGC/UAB; UCL-DRC EOAD; ADSP. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<https://adni.loni.usc.edu/>). Full consortium acknowledgements and funding sources are listed in the Supplementary Note. The work in this manuscript was carried out on the Cartesius supercomputer, which is embedded in the Dutch national e-infrastructure with the support of SURF Cooperative. Computing hours were granted to H. H. by the Dutch Research Council ('100plus': project# vuh15226, 15318, 17232, and 2020.030; 'Role of VNTRs in AD'; project# 2022.31, 'Alzheimer's Genetics Hub' project# 2022.38).

## Author contributions

Conceived the study: HH<sup>1</sup> and OMA; Wrote the manuscript: HH<sup>1</sup>, MdW, NT, SvdL, MH, OMA; Genetic Analyses: HH<sup>1</sup>, MdW, NT, SvdL, CdG, MV, RvS, MH, OMA. DMDM analysis: GM, AMGJ, JGO, HH, and OMA. Participant collection and sequencing from the ADES, ADSP, StEP-AD, Knight ADRC, UCSF/NYGC/UAB cohorts: SA, NA, PA, GWB, CB<sup>1</sup>, CB<sup>2</sup>, JCB, AB, PB, FB, JB, DC, CC<sup>1</sup>, JC, JNC, CC<sup>2</sup>, AD, J-FD<sup>1</sup>, SD, J-FD<sup>2</sup>, ND, ALDS, OD-I, CMvD, LAF, MVF, WMvdf, NCF, DG<sup>1</sup>, EG, JJP, MG, BG-B, DG<sup>2</sup>, YLG, RG, JLH, CH, HH<sup>2</sup>, MAI; MKI; IEJ, AK, RK, J-CL, ML; AWL, AL, LL, MAMM, RM, ERM, CM, RM, SM, PM, AM, MOM, KM, RMM, BN, ACN, VN, GN, PJN, FP, PP, MAP-V, YALP, OQ, AR, RR<sup>1</sup>; RR<sup>2</sup>, MJTR, A-CR, SGR-H, FR, SR, JGJvR, NSR, SS<sup>1</sup>, PS-J, GDS, PS, JMS, DS<sup>1</sup>, SS<sup>2</sup>, DS<sup>2</sup>; RS, EAS, SS<sup>3</sup>, GS, JCVs, BT, AGU, PJV, MW, DW, L-SW, JW, JSY, AZ. CB<sup>1</sup>: Céline Bellenguez; CB<sup>2</sup>: Claudine Berr; CC<sup>1</sup>: Camille Charbonnier; CC<sup>2</sup>: Carlos Cruchaga; J-FD<sup>1</sup>: Jean-François Dartigue; J-FD<sup>2</sup>: Jean-François Deleuze; DG<sup>1</sup>: Daniela Galimberti; DG<sup>2</sup>: Detelina Grozeva; HH<sup>1</sup> Henne Holstege; HH<sup>2</sup> Holger Hummerich; RR<sup>1</sup>: Rachel Raybould; RR<sup>2</sup>: Richard Redon; SS<sup>1</sup>: Salha Saad; SS<sup>2</sup>: Sudha Seshadri; SS<sup>3</sup>: Sandro Sorbi

## Funding

HH and OMA are a part of the EU Joint Programme-Neurodegenerative Disease Research (JPND) Working Group SORLA-FIX under the 2019 "Personalized Medicine" call (JPND2019-466-197, ZonMW 733051110, Danish Innovation Foundation and the Velux Foundation Denmark). H.H., S.L., are recipients of ABOARD, and NT is appointed at ABOARD, a public-private partnership receiving funding from ZonMW (#73305095007) and Health-Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). SvdL is recipient of ZonMW funding (#733050512). HH was supported by the Hans und Ilse Breuer Stiftung (2020), Dioraphte (16020404) and the HorstingStuit Foundation (2018). OMA is recipient of funding related to the 2022 Research Prize from the Alzheimers Research Foundation Denmark.

## Data availability

All 646 identified *SORL1* coding variants are listed in the recent release of the Alzforum Mutation database [64]. (<https://www.alzforum.org/mutations/sorl1>). Genomes from contributing cohorts are shared on the Alzheimer Genetics Hub: <http://www.alzheimergenetics.org>.

## Declarations

### Ethics approval and consent to participate

For consent and sample description see supplementary data 1.1.

### Consent for publication

Not applicable.

### Competing interest

HH has a collaboration contract with Muna Therapeutics, PacBio, Neurimmune and Alchemab. She serves in the scientific advisory boards of Muna Therapeutics and is an external advisor for Retromer Therapeutics. O.M.A. is an advisor of Retromer Therapeutics and has financial interests, but this company played no part in the study.

### Author details

<sup>1</sup>Department of Biomedicine, Aarhus University, Aarhus, Denmark

<sup>2</sup>Department of Human Genetics, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

<sup>3</sup>Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

<sup>4</sup>Alzheimer Center Amsterdam, Neurology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

<sup>5</sup>Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands

<sup>6</sup>Clinical Genetics, Human Genetics, Amsterdam UMC, Amsterdam, The Netherlands

<sup>7</sup>Genome Analysis Laboratory, Human Genetics, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

<sup>8</sup>Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands

<sup>9</sup>LACDR, Leiden, The Netherlands

<sup>10</sup>Nuffield Department of Population Health Oxford University, Oxford, UK

<sup>11</sup>Univ. Lille, Inserm, CHU Lille, Institut Pasteur Lille, LabEx DISTALZ-U1167-RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France

<sup>12</sup>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA

<sup>13</sup>Univ Montpellier, Inserm, INM (Institute for Neurosciences of Montpellier), Montpellier, France

<sup>14</sup>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA

<sup>15</sup>Université Paris-Saclay, CEA, Centre National de Recherche En Génomique Humaine, Evry, France

<sup>16</sup>Experimental Neuro-Psychobiology Laboratory, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy

<sup>17</sup>Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA

<sup>18</sup>Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA

- <sup>19</sup>Departments of Genetics and CNRMAJ, Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Rouen F-76000, France
- <sup>20</sup>Memory Unit, Neurology Department and Institut de Recerca Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Quintí 77-79, Barcelona 08041, Spain
- <sup>21</sup>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- <sup>22</sup>Psychiatry Department, Washington University School of Medicine, St Louis, MO, USA
- <sup>23</sup>Neurogenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA
- <sup>24</sup>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA
- <sup>25</sup>Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- <sup>26</sup>University Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France
- <sup>27</sup>Department of Neurology, Bordeaux University Hospital, Bordeaux, France
- <sup>28</sup>UKDRI at Cardiff, School of Medicine, Cardiff University, Cardiff, UK
- <sup>29</sup>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
- <sup>30</sup>Framingham Heart Study, Framingham, MA, USA
- <sup>31</sup>Department of Neurology, Boston University School of Medicine, Boston, MA, USA
- <sup>32</sup>Department of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA
- <sup>33</sup>Department of Epidemiology, Boston University, Boston, MA, USA
- <sup>34</sup>UK Dementia Research Institute at UCL, London, UK
- <sup>35</sup>Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
- <sup>36</sup>University of Milan, Milan, Italy
- <sup>37</sup>Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy
- <sup>38</sup>Univ Brest, Inserm, EFS, CHU Brest, UMR 1078, GGB, Brest F-29200, France
- <sup>39</sup>Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK
- <sup>40</sup>Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA, USA
- <sup>41</sup>Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
- <sup>42</sup>Clinical and Experimental Science, Faculty of Medicine, University of Southampton, Southampton, UK
- <sup>43</sup>MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK
- <sup>44</sup>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- <sup>45</sup>Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
- <sup>46</sup>McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada
- <sup>47</sup>HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
- <sup>48</sup>Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Reproduction and Development Research Institute Amsterdam, Amsterdam, The Netherlands
- <sup>49</sup>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA
- <sup>50</sup>Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy
- <sup>51</sup>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA
- <sup>52</sup>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA
- <sup>53</sup>Division of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
- <sup>54</sup>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- <sup>55</sup>Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
- <sup>56</sup>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
- <sup>57</sup>Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence, Florence, Italy
- <sup>58</sup>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
- <sup>59</sup>Penn Neurodegeneration Genomics Center, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
- <sup>60</sup>Genomic and Molecular Epidemiology (GAME) Lab, School of Biosciences and Veterinary Medicine, University of Camerino (UNICAM), 62032 Camerino, Italy
- <sup>61</sup>Univ. Lille, Inserm, CHU Lille, UMR1172, Resources and Research Memory Center (MRRC) of Distal, Licend, Lille, France
- <sup>62</sup>Unit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
- <sup>63</sup>The Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
- <sup>64</sup>Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy
- <sup>65</sup>Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- <sup>66</sup>Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
- <sup>67</sup>German Center for Neurodegenerative Diseases (DZNE, Bonn), Bonn, Germany
- <sup>68</sup>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Medical Faculty, Bonn, Germany
- <sup>69</sup>Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du thorax, Nantes, France
- <sup>70</sup>Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
- <sup>71</sup>Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain
- <sup>72</sup>MRC UK Dementia Research Institute, Division of Psychological Medicine, Cardiff University, Cardiff, UK
- <sup>73</sup>Memory and Aging Center, Department of Neurology Weill Institute for Neurosciences, and Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
- <sup>74</sup>Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, Copenhagen DK2200, Denmark

Received: 20 February 2025 / Accepted: 5 October 2025

Published online: 01 December 2025

## References

1. Young JE, Holstege H, Andersen OM, Petsko GA, Small SA. On the causal role of retromer-dependent endosomal recycling in Alzheimer's disease. *Nat Cell Biol.* 2023;25(10):1394–97.
2. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet.* 2007;39(2):168–77.
3. Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. *Hum Mutat.* 2008;29(5):769–70.
4. Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, et al. Coding mutations in SORL1 and Alzheimer disease. *Ann Neurol.* 2015;77(2):215–27.
5. Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C, et al. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet.* 2013;45(12):1452–58.
6. Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhito S, Zou F, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. *Arch Neurol.* 2011;68(1):99–106.
7. Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Llado A, et al. A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. *Acta Neuropathologica.* 2016;132(2):213–24.
8. Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. *Mol Psychiatry.* 2012;17(9):875–79.
9. Nicolas G, Charbonnier C, Wallon D, Quenez O, Bellenguez C, Grenier-Boley B, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. *Mol Psychiatry.* 2015.

10. Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. *Eur J Hum Genet*. 2017;25(8):973–81.
11. Bellenguez C, Charbonnier C, Grenier-Boley B, Quenez O, Le Guennec K, Nicolas G, et al. Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. *Neurobiol Aging*. 2017;59:220 e1–e9.
12. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76, 156 human genomes. *Nature*. 2024;626.
13. Holstege H, Hulsman M, Charbonnier C, Grenier-Boley B, Quenez O, Grozeva D, et al. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. *Nat Genet*. 2022;54(12):1786–94.
14. Schramm C, Charbonnier C, Zaréa A, Lacour M, Wallon D, Andriuta D, et al. Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes. *Genome Med*. 2022;14(1).
15. Olivas MC, Griswold AJ, Saldarriaga-Mayo A, Mena P, Rodriguez R, Adams L, et al. Novel stop-gain SORL1 mutation in a Peruvian family with Alzheimer's disease of the PeADI study (P6-9.017). *Neurology*. 2024;102(17\_supplement\_1).
16. Campion D, Charbonnier C, Nicolas G. SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. *Acta Neuropathologica*. 2019.
17. Thonberg H, Chiang HH, Lilius L, Forsell C, Lindstrom AK, Johansson C, et al. Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene. *Acta Neuropathologica Commun*. 2017;5(1):43.
18. der Lee SJ V, Minderhoud C, van Spaendonck R, Meijers-Heijboer H, der Flier Wm V, Scheltens P, et al. Is Sorl1 an autosomal dominant Alzheimer gene? *Alzheimer's Dementia*. 2018;14(7).
19. Jensen AMG, Raska J, Fojtik P, Monti G, Lunding M, Bartova S, et al. The SORL1 p.Y1816C variant causes impaired endosomal dimerization and autosomal dominant Alzheimer's disease. *Proc Natl Acad Sci USA*. 2024;121(37):e2408262121.
20. Fazeli E, Child DD, Bucks SA, Stovarsky M, Edwards G, Rose SE, et al. A familial missense variant in the Alzheimer's disease gene SORL1 impairs its maturation and endosomal sorting. *Acta Neuropathologica*. 2024;147(1).
21. Lakshmana MK, Tejada Moreno JA, Villegas Lanau A, Madrigal Zapata L, Baena Pineda AY, Velez Hernandez J, et al. Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian family. *PLoS One*. 2022;17(7).
22. Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer disease revisited. *Alzheimer's Dementia: J Alzheimer's Assoc*. 2016.
23. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu C-E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. *Brain*. 2010;133(4):1143–54.
24. Thordardottir S, Rodriguez-Vieitez E, Almkvist O, Ferreira D, Saint-Aubert L, Kinhlult-Ståhlbom A, et al. Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. *Alzheimer's Res Ther*. 2018;10(1).
25. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res*. 2014;42(D1):D980–5.
26. Christensen SK, Narimatsu Y, Simoes S, Goth CK, Vægter CB, Small SA, et al. Endosomal trafficking is required for glycosylation and normal maturation of the Alzheimer's-associated protein sorLA. *BioRxiv Preprint*. 2020.
27. Pedersen NB, Wang S, Narimatsu Y, Yang Z, Halim A, Kt-Bg S, et al. Low density lipoprotein receptor class a repeats are O-Glycosylated in linker regions. *J Biol Chem*. 2014;289(25):17312–24.
28. Xie T, Xu G, Liu Y, Quade B, Lin W, X-C B. Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex. *Proc Natl Acad Sci*. 2023;120(23).
29. Andersen OM, Christensen LL, Christensen PA, Sørensen ES, Jacobsen C, Moestrup SK, et al. Identification of the minimal functional unit in the low density lipoprotein receptor-related protein for binding the receptor-associated protein (RAP). *J Biol Chem*. 2000;275(28):21017–24.
30. Bjarnadottir K, Monti G, Steinberg S, Gunnarsdottir K, Snaedal J, Jonsson PV, et al. Recent SORL1 missense variant causing a SORLA maturation defect is associated with Alzheimer's disease. In preparation. 2023.
31. Jensen AMG, Kitago Y, Fazeli E, Vægter CB, Small SA, Petsko GA, et al. Dimerization of the Alzheimer's disease pathogenic receptor SORLA regulates its association with retromer. *Proc Natl Acad Sci*. 2023;120(4).
32. Fjorback AW, Seaman M, Gustafsen C, Mehmedbasic A, Gokool S, Wu C, et al. Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. *J Neurosci*. 2012;32(4):1467–80.
33. Peterson TA, Adadey A, Santana-Cruz I, Sun Y, Winder A, Kann MG. DMDM: domain mapping of disease mutations. *Bioinformatics*. 2010;26(19):2458–59.
34. Van Der Lee SJ, Hulsman M, Van Spaendonck R, Van Der Schaar J, Dijkstra J, Tesi N, et al. Prevalence of pathogenic variants and eligibility criteria for genetic testing in patients who visit a memory clinic. *Neurology*. 2025;104(4):e210273.
35. Nicolas G, Zarea A, Lacour M, Quenez O, Rousseau S, Richard AC, et al. Assessment of Mendelian and risk-factor genes in Alzheimer disease: a prospective nationwide clinical utility study and recommendations for genetic screening. *Genet Med*. 2024;26(5):101082.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. *Neurology*. 1984;34(7):939–44.
37. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dementia: J Alzheimer's Assoc*. 2011;7(3):263–69.
38. Thornton T, Dou J, Sun B, Sim X, Hughes JD, Reilly DF, et al. Estimation of kinship coefficient in structured and admixed populations using sparse sequencing data. *PLoS Genet*. 2017;13(9).
39. Toft M, Miyashita A, Koike A, Jun G, Wang L-S, Takahashi S, et al. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and caucasians. *PLoS One*. 2013;8(4).
40. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. *Am J Hum Genet*. 2016;99(4):877–85.
41. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141, 456 humans. *Nature*. 2020;581(7809):434–43.
42. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. *Cell*. 2019;176(3):535–48.e24.
43. Bellenguez C, Küçükali F, Jansen IE, Kleindam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet*. 2022;54(4):412–36.
44. Kitago Y, Nagae M, Nakata Z, Yagi-Utsumi M, Takagi-Niidome S, Mihara E, et al. Structural basis for amyloidogenic peptide recognition by sorLA. *Nat Struct Mol Biol*. 2015;22(3):199–206.
45. Cheng J, Novati G, Pan J, Bycroft C, Žemgulytė A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. *Science*. 2023;381:6664.
46. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease. *Neurology*. 2014;83(3):253–60.
47. Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease. *Neurol Genet*. 2020;6(5).
48. Grangeon L, Charbonnier C, Zarea A, Rousseau S, Rovelet-Lecrux A, Bendetowicz D, et al. Phenotype and imaging features associated with APP duplications. *Alzheimer's Res Ther*. 2023;15(1).
49. Brayne C, Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. *PLoS Med*. 2017;14(3).
50. van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *The Lancet Neurol*. 2018;17(5):434–44.
51. Blacklow SC, Kim PS. Protein folding and calcium binding defects arising from familial hypercholesterolemia mutations of the LDL receptor. *Nat Struct Mol Biol*. 1996;3(9):758–62.
52. Fass D, Blacklow S, Kim PS, Berger JM. Molecular basis of familial hypercholesterolemia from structure of LDL receptor module. *Nature*. 1997;388(6643):691–93.
53. Rovelet-Lecrux A, Feuillette S, Miguel L, Schramm C, Pernet S, Quenez O, et al. Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease. *Acta Neuropathologica Commun*. 2021;9(1).



54. Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T, et al. Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. *Sci Transl Med*. 2014;6(223):223ra20.
55. Fazeli E, Fazeli E, Fojtik P, Holstege H, Andersen OM. Functional characterization of SORL1 variants in cell-based assays to investigate variant pathogenicity. *Philos Trans R Soc Lond B Biol Sci*. 2024;379(1899):20220377.
56. de Waal MWJ, van der Lee SJ, Lunding M, Boonkamp L, Barrett N, Monti G, et al. Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants. In preparation. in preparation. 2024.
57. Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. *Nat Commun*. 2020;11(1).
58. Le Guennec K, Tubeuf H, Hannequin D, Wallon D, Quenez O, Rousseau S, et al. Biallelic loss of function of SORL1 in an early onset Alzheimer's disease patient. *J Alzheimer's Disease*. 2018;62(2):821–31.
59. Dyle MC, Kolakada D, Cortazar MA, Jagannathan S. How to get away with nonsense: mechanisms and consequences of escape from nonsense-mediated RNA decay. *WIREs RNA*. 2019;11(1).
60. Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans EA, Rozemuller AJ, et al. Rare genetic variant in SORL1 May increase penetrance of Alzheimer's disease in a family with several generations of APOE-varepsilon4 homozygosity. *J Alzheimer's Disease: JAD*. 2017;56(1):63–74.
61. Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, González-Neira A, et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. *Genome Med*. 2022;14(1).
62. Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline testing in patients with breast cancer: ASCO-Society of surgical oncology guideline. *J Clin Oncol*. 2024;42(5):584–604.
63. Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C, et al. Phenotypic similarities between late-onset autosomal dominant and sporadic Alzheimer disease. *JAMA Neurol*. 2016;73(9).
64. Alzforum Mutation Database SORL1 [Internet]. 2023.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.